Spain
· Delayed Price · Currency is EUR Pharma Mar Statistics
Total Valuation
Pharma Mar has a market cap or net worth of EUR 712.78 million. The enterprise value is 617.02 million.
| Market Cap | 712.78M |
| Enterprise Value | 617.02M |
Important Dates
The next estimated earnings date is Friday, October 25, 2024.
| Earnings Date | Oct 25, 2024 |
| Ex-Dividend Date | Jun 12, 2024 |
Share Statistics
Pharma Mar has 17.54 million shares outstanding. The number of shares has decreased by -4.79% in one year.
| Shares Outstanding | 17.54M |
| Shares Change (YoY) | -4.79% |
| Shares Change (QoQ) | +0.68% |
| Owned by Insiders (%) | 11.87% |
| Owned by Institutions (%) | 7.48% |
| Float | 13.61M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 28.82 |
| PS Ratio | 4.49 |
| PB Ratio | 3.93 |
| P/FCF Ratio | n/a |
| PEG Ratio | 0.27 |
Enterprise Valuation
| EV / Earnings | -350.38 |
| EV / Sales | 3.89 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -20.76 |
Financial Position
The company has a current ratio of 2.55, with a Debt / Equity ratio of 21.71.
| Current Ratio | 2.55 |
| Quick Ratio | 1.88 |
| Debt / Equity | 21.71 |
| Debt / EBITDA | n/a |
| Debt / FCF | -1.32 |
| Interest Coverage | -4.15 |
Financial Efficiency
Return on equity (ROE) is -0.90% and return on invested capital (ROIC) is -2.42%.
| Return on Equity (ROE) | -0.90% |
| Return on Assets (ROA) | -1.70% |
| Return on Capital (ROIC) | -2.42% |
| Revenue Per Employee | 311,988 |
| Profits Per Employee | -3,460 |
| Employee Count | 509 |
| Asset Turnover | 0.47 |
| Inventory Turnover | 0.25 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +14.35% in the last 52 weeks. The beta is 0.20, so Pharma Mar's price volatility has been lower than the market average.
| Beta (5Y) | 0.20 |
| 52-Week Price Change | +14.35% |
| 50-Day Moving Average | 37.79 |
| 200-Day Moving Average | 35.69 |
| Relative Strength Index (RSI) | 57.33 |
| Average Volume (20 Days) | 33,681 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Pharma Mar had revenue of EUR 158.80 million and -1.76 million in losses. Loss per share was -0.10.
| Revenue | 158.80M |
| Gross Profit | 148.35M |
| Operating Income | -9.21M |
| Pretax Income | -6.35M |
| Net Income | -1.76M |
| EBITDA | -6.20M |
| EBIT | -9.21M |
| Loss Per Share | -0.10 |
Balance Sheet
The company has 135.15 million in cash and 39.38 million in debt, giving a net cash position of 95.76 million or 5.46 per share.
| Cash & Cash Equivalents | 135.15M |
| Total Debt | 39.38M |
| Net Cash | 95.76M |
| Net Cash Per Share | 5.46 |
| Equity (Book Value) | 181.38M |
| Book Value Per Share | 10.34 |
| Working Capital | 136.24M |
Cash Flow
In the last 12 months, operating cash flow was -9.58 million and capital expenditures -20.15 million, giving a free cash flow of -29.72 million.
| Operating Cash Flow | -9.58M |
| Capital Expenditures | -20.15M |
| Free Cash Flow | -29.72M |
| FCF Per Share | -1.69 |
Margins
Gross margin is 93.42%, with operating and profit margins of -5.80% and -1.11%.
| Gross Margin | 93.42% |
| Operating Margin | -5.80% |
| Pretax Margin | -4.00% |
| Profit Margin | -1.11% |
| EBITDA Margin | -3.90% |
| EBIT Margin | -5.80% |
| FCF Margin | -18.72% |
Dividends & Yields
This stock pays an annual dividend of 0.65, which amounts to a dividend yield of 1.60%.
| Dividend Per Share | 0.65 |
| Dividend Yield | 1.60% |
| Dividend Growth (YoY) | -38.27% |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 4.79% |
| Shareholder Yield | 6.39% |
| Earnings Yield | -0.26% |
| FCF Yield | -4.17% |
Stock Splits
The last stock split was on July 22, 2020. It was a reverse split with a ratio of 0.0833333333.
| Last Split Date | Jul 22, 2020 |
| Split Type | Reverse |
| Split Ratio | 0.0833333333 |